These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

856 related items for PubMed ID: 19835971

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients.
    Osunkwo I, Bessmertny O, Harrison L, Cheung YK, Van de Ven C, del Toro G, Garvin J, George D, Bradley MB, Wolownik K, Wischhover C, Levy J, Skerrett D, Cairo MS.
    Biol Blood Marrow Transplant; 2004 Apr; 10(4):246-58. PubMed ID: 15077223
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A Phase I study of gemtuzumab ozogamicin (GO) in combination with busulfan and cyclophosphamide (Bu/Cy) and allogeneic stem cell transplantation in children with poor-risk CD33+ AML: a new targeted immunochemotherapy myeloablative conditioning (MAC) regimen.
    Satwani P, Bhatia M, Garvin JH, George D, Dela Cruz F, Le Gall J, Jin Z, Schwartz J, Duffy D, van de Ven C, Foley S, Hawks R, Morris E, Baxter-Lowe LA, Cairo MS.
    Biol Blood Marrow Transplant; 2012 Feb; 18(2):324-9. PubMed ID: 22079471
    [Abstract] [Full Text] [Related]

  • 6. A Pilot Study of Continuous Infusion of Mycophenolate Mofetil for Prophylaxis of Graft-versus-Host-Disease in Pediatric Patients.
    Windreich RM, Goyal RK, Joshi R, Kenkre TS, Howrie D, Venkataramanan R.
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):682-689. PubMed ID: 26740371
    [Abstract] [Full Text] [Related]

  • 7. Age-dependency of mycophenolate mofetil dosing in combination with tacrolimus after pediatric renal transplantation.
    Filler G, Foster J, Berard R, Mai I, Lepage N.
    Transplant Proc; 2004 Jun; 36(5):1327-31. PubMed ID: 15251324
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Risk factors associated with kidney injury and the impact of kidney injury on overall survival in pediatric recipients following allogeneic stem cell transplant.
    Satwani P, Bavishi S, Jin Z, Jacobson JS, Baker C, Duffy D, Lowe L, Morris E, Cairo MS.
    Biol Blood Marrow Transplant; 2011 Oct; 17(10):1472-80. PubMed ID: 21338706
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis.
    Pérez-Simón JA, Martino R, Caballero D, Valcarcel D, Rebollo N, de la Cámara R, de Oteiza JP, Heras I, Calvo MV, Sierra J, San Miguel JF, Grupo Español de Trasplante Hematopoyético (GETH).
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):664-71. PubMed ID: 18489992
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of tacrolimus/mycophenolate mofetil as acute graft-versus-host disease prophylaxis and the impact of subtherapeutic tacrolimus levels in children after matched sibling donor allogeneic hematopoietic cell transplantation.
    Offer K, Kolb M, Jin Z, Bhatia M, Kung AL, George D, Garvin JH, Robinson C, Sosna J, Karamehmet E, Satwani P.
    Biol Blood Marrow Transplant; 2015 Mar; 21(3):496-502. PubMed ID: 25536217
    [Abstract] [Full Text] [Related]

  • 13. Intensified Mycophenolate Mofetil Dosing and Higher Mycophenolic Acid Trough Levels Reduce Severe Acute Graft-versus-Host Disease after Double-Unit Cord Blood Transplantation.
    Harnicar S, Ponce DM, Hilden P, Zheng J, Devlin SM, Lubin M, Pozotrigo M, Mathew S, Adel N, Kernan NA, O'Reilly R, Prockop S, Scaradavou A, Hanash A, Jenq R, van den Brink M, Giralt S, Perales MA, Young JW, Barker JN.
    Biol Blood Marrow Transplant; 2015 May; 21(5):920-5. PubMed ID: 25687796
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Targeting mycophenolate mofetil for graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation.
    Haentzschel I, Freiberg-Richter J, Platzbecker U, Kiani A, Schetelig J, Illmer T, Ehninger G, Schleyer E, Bornhäuser M.
    Bone Marrow Transplant; 2008 Jul; 42(2):113-20. PubMed ID: 18362900
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics of intravenous mycophenolate mofetil after allogeneic blood stem cell transplantation.
    Jenke A, Renner U, Richte M, Freiberg-Richter J, Platzbecker U, Helwig A, Thiede HM, Schäfer-Eckart K, Ehninger G, Bornhäuser M.
    Clin Transplant; 2001 Jun; 15(3):176-84. PubMed ID: 11389708
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.